MAPT and Alzheimer disease: More specifically, a longitudinal study in patients with MCI and AD dementia demonstrated that increased plasma NfL levels over time were correlated with poorer global cognitive performance and AD biomarkers in the CSF at baseline (low amyloid beta 42, high total tau and high phosphorylated tau levels) (43).